[go: up one dir, main page]

WO2005001022A3 - Procedes et compositions permettant de renforcer une reponse immune - Google Patents

Procedes et compositions permettant de renforcer une reponse immune Download PDF

Info

Publication number
WO2005001022A3
WO2005001022A3 PCT/US2004/011085 US2004011085W WO2005001022A3 WO 2005001022 A3 WO2005001022 A3 WO 2005001022A3 US 2004011085 W US2004011085 W US 2004011085W WO 2005001022 A3 WO2005001022 A3 WO 2005001022A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
immune response
enhancing immune
irm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/011085
Other languages
English (en)
Other versions
WO2005001022A2 (fr
Inventor
Richard L Miller
Mark A Tomai
Ross M Kedl
Isidro Angelo E Zarraga
Ronnie Ortiz
James D Stoesz
Paul D Wightman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/640,904 external-priority patent/US7427629B2/en
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Priority to JP2006532393A priority Critical patent/JP2007514644A/ja
Priority to CA002521662A priority patent/CA2521662A1/fr
Priority to EP04775877A priority patent/EP1617872A4/fr
Priority to AU2004252409A priority patent/AU2004252409A1/en
Publication of WO2005001022A2 publication Critical patent/WO2005001022A2/fr
Publication of WO2005001022A3 publication Critical patent/WO2005001022A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des procédés et des compositions permettant de renforcer une réponse immune vis-à-vis d'un composé modificateur de réponse immune, par dépôt dans une zone tissulaire localisée de préparation de dépôt modificateur de réponse immune qui assure une durée de résidence étendue de modificateur de réponse immune actif dans ladite zone.
PCT/US2004/011085 2003-04-10 2004-04-09 Procedes et compositions permettant de renforcer une reponse immune Ceased WO2005001022A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006532393A JP2007514644A (ja) 2003-04-10 2004-04-09 免疫反応を向上させる方法および組成物
CA002521662A CA2521662A1 (fr) 2003-04-10 2004-04-09 Procedes et compositions permettant de renforcer une reponse immune
EP04775877A EP1617872A4 (fr) 2003-04-10 2004-04-09 Procedes et compositions permettant de renforcer une reponse immune
AU2004252409A AU2004252409A1 (en) 2003-04-10 2004-04-09 Methods and compositions for enhancing immune response

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US46214003P 2003-04-10 2003-04-10
US60/462,140 2003-04-10
US10/640,904 2003-08-14
US10/640,904 US7427629B2 (en) 2002-08-15 2003-08-14 Immunostimulatory compositions and methods of stimulating an immune response
US51525603P 2003-10-29 2003-10-29
US60/515,256 2003-10-29
US53370303P 2003-12-31 2003-12-31
US60/533,703 2003-12-31
US54542404P 2004-02-18 2004-02-18
US54554204P 2004-02-18 2004-02-18
US60/545,424 2004-02-18
US60/545,542 2004-02-18

Publications (2)

Publication Number Publication Date
WO2005001022A2 WO2005001022A2 (fr) 2005-01-06
WO2005001022A3 true WO2005001022A3 (fr) 2005-09-15

Family

ID=34923557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011085 Ceased WO2005001022A2 (fr) 2003-04-10 2004-04-09 Procedes et compositions permettant de renforcer une reponse immune

Country Status (5)

Country Link
EP (1) EP1617872A4 (fr)
JP (1) JP2007514644A (fr)
AU (1) AU2004252409A1 (fr)
CA (1) CA2521662A1 (fr)
WO (1) WO2005001022A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314535B2 (en) 2009-09-03 2016-04-19 Curevac Ag Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US9572874B2 (en) 2008-09-30 2017-02-21 Curevac Ag Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006007433A1 (de) * 2006-02-17 2007-08-23 Curevac Gmbh Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
EP2046954A2 (fr) 2006-07-31 2009-04-15 Curevac GmbH Acide nucléique de formule (i): gixmgn, ou(ii): cixmcn, en particulier en tant qu'agent/adjuvant immunostimulant
WO2009030254A1 (fr) 2007-09-04 2009-03-12 Curevac Gmbh Complexes d'arn et de peptides cationiques pour transfection et immunostimulation
HUE025027T2 (en) 2008-01-31 2016-07-28 Curevac Gmbh (NuGiXmGnNv) nucleic acids and derivatives of the formula as immunostimulants / adjuvants
LT2341933T (lt) 2008-10-24 2018-04-10 Glaxosmithkline Biologicals Sa Lipidinti imidazochinolino dariniai
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
WO2013113326A1 (fr) 2012-01-31 2013-08-08 Curevac Gmbh Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide
JP6896421B2 (ja) 2013-08-21 2021-06-30 キュアバック アーゲー 呼吸器合胞体ウイルス（ｒｓｖ）ワクチン
AU2014347059B2 (en) * 2013-11-05 2017-09-07 Solventum Intellectual Properties Company Sesame oil based injection formulations
EP3129050A2 (fr) 2014-04-01 2017-02-15 CureVac AG Complexe cargo de support polymère à utiliser comme agent immunostimulant ou comme adjuvant
JP6764930B2 (ja) 2015-09-29 2020-10-07 大日本住友製薬株式会社 アデニンコンジュゲート化合物およびそのワクチンアジュバントとしての使用
EP3868741B1 (fr) 2015-10-07 2023-08-30 Sumitomo Pharma Co., Ltd. Composition comprenant un composé dérivé de la pyrimidine et un antigène dérivé d'un pathogène
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
US12059462B2 (en) 2018-07-23 2024-08-13 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447724A (en) * 1990-05-17 1995-09-05 Harbor Medical Devices, Inc. Medical device polymer
US6486214B1 (en) * 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194581A (en) * 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6245776B1 (en) * 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1360486A2 (fr) * 2000-12-08 2003-11-12 3M Innovative Properties Company Procede de criblage permettant d'identifier des composes qui induisent de maniere selective la production d'interferon alpha
CN1292751C (zh) * 2002-04-23 2007-01-03 四川大学 皮肤局部用咪喹莫特或其衍生物脂质体及其制备方法和用途
CN1671412B (zh) * 2002-08-15 2010-05-26 3M创新有限公司 免疫刺激组合物及刺激免疫反应的方法
EP1578843B1 (fr) * 2002-12-31 2008-07-09 Nektar Therapeutics Al, Corporation Procedes de formation d'hydrogels au moyen de compositions de thiosulfonate et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447724A (en) * 1990-05-17 1995-09-05 Harbor Medical Devices, Inc. Medical device polymer
US6486214B1 (en) * 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIBSON S.J. ET AL: "Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod", CELL IMMUNOL, vol. 218, 2002, pages 74 - 86, XP002985828 *
See also references of EP1617872A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572874B2 (en) 2008-09-30 2017-02-21 Curevac Ag Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US9314535B2 (en) 2009-09-03 2016-04-19 Curevac Ag Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids

Also Published As

Publication number Publication date
EP1617872A4 (fr) 2011-09-07
CA2521662A1 (fr) 2005-01-06
JP2007514644A (ja) 2007-06-07
WO2005001022A2 (fr) 2005-01-06
EP1617872A2 (fr) 2006-01-25
AU2004252409A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
WO2005001022A3 (fr) Procedes et compositions permettant de renforcer une reponse immune
WO2005055932A3 (fr) Combinaisons therapeutiques et methodes faisant appel a des composes irm
WO2006093524A3 (fr) Conjugues antigene-glucide
WO2004082822A3 (fr) Procedes permettant d'isoler la forme i cristalline de la 5-azacytidine
WO2004080430A3 (fr) Procedes pour ameliorer la qualite de la peau
WO2006031878A3 (fr) Composés à base d'imidazoquinoline
WO2003072035A8 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
WO2004041170A9 (fr) Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
WO2006015371A3 (fr) Antagonistes anti-cmet humanises
WO2006023651A3 (fr) Traitement prolonge de la sclerose en plaques
WO2004024097A9 (fr) Compositions et methodes de traitement de maladies de nature immune
WO2005019258A3 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
WO2004078138A3 (fr) Traitement prophylactique de la neoplasie epidermique induite par les uv
EP1516612A3 (fr) Mascara en deux étapes
WO2004024068A3 (fr) Nouvelles composition et methodes servant au traitement de maladies associees au systeme immunitaire
WO2003051294A3 (fr) Compositions acaricides et methodes associees
WO2006130399A3 (fr) Combinaisons et methodes therapeutiques comprenant des composes irm
WO2005009928A3 (fr) Preparation et utilisation d'agents d'alkylation
WO2004087073A3 (fr) Traitement d'etats de demyelinisation
WO2005028474A3 (fr) Inhibiteurs de chk-1
EP1344515A4 (fr) Produits de beaute pour la peau
WO2003007900A3 (fr) Traitement de la peau
WO2004024076A8 (fr) Compositions et methodes pour le traitement de maladies du systeme immunitaire
WO2009057954A3 (fr) Composition pour le traitement de la stéatose hépatique
AU2003212344A1 (en) Use of extracts from olive trees as anti-dandruff agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2521662

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004252409

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006532393

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004252409

Country of ref document: AU

Date of ref document: 20040409

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004252409

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004775877

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004775877

Country of ref document: EP